[Conduction velocity and relative refractory period of the sural nerve in patients treated with ergot alkaloids].
Relative refractory period and sural nerve conduction velocity were estimated in 30 probands and 52 patients treated with ergotamine tartrate using surface electrodes. A significant reduction in sural nerve relative refractory period could be correlated to an ergotamine dosage limited within therapeutical range. Patients under treatment without complaints even had a significant shorter relative refractory period compared to patients suffering from dysesthesia (p less than 0.01). Sural nerve conduction velocity showed a similar but not significant change in the tested patients.
D000328:Adult; D004878:Ergotamine / Q000627:therapeutic use*; D005260:Female; D006261:Headache / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy / Q000503:physiopathology; D009431:Neural Conduction / Q000187:drug effects; D012032:Refractory Period, Electrophysiological / Q000187:drug effects; D013127:Spinal Nerves / Q000503:physiopathology*; D013497:Sural Nerve / Q000187:drug effects / Q000503:physiopathology*
D004878:Ergotamine
Die Nervus suralis-Leitgeschwindigkeit und die relative Refraktärperiode bei Patienten unter einer Ergotalkaloidtherapie.